Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Eye

• Publication date

  2015-01-16

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/eye.2014.329PMID 25592118PMCID PMC4816356
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fcγ receptor upregulation is associated with immune complex inflammation in the mouse retina and early age-related macular degeneration.

  2014cited by this paper
• Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.

  2014cited by this paper
• Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.

  2014cited by this paper
• Intraocular pharmacokinetics of ranibizumab in vitrectomized versus nonvitrectomized eyes.

  2014cited by this paper
• Expression of neonatal Fc receptor in the eye.

  2014cited by this paper
• Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.

  2014cited by this paper
• Pharmacokinetics of Intravitreally Injected Bevacizumab in Vitrectomized Eyes

  2013cited by this paper
• Pharmacokinetic Properties of Intravitreal I-124-Aflibercept in a Rabbit Model Using PET/CT

  2012cited by this paper
• Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results.

  2012cited by this paper
• Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.

  2012cited by this paper
• One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema.

  2012cited by this paper
• Double Anti-angiogenic and Anti-inflammatory Protein Valpha Targeting VEGF-A and TNF-α in Retinopathy and Psoriasis*

  2011cited by this paper
• Distinct Aggregation Mechanisms of Monoclonal Antibody Under Thermal and Freeze-Thaw Stresses Revealed by Hydrogen Exchange

  2011cited by this paper
• Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.

  2010cited by this paper
• Pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits

  2010cited by this paper
• Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.

  2010cited by this paper
• FcRn receptor-mediated pharmacokinetics of therapeutic IgG in the eye

  2009cited by this paper
• Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.

  2009cited by this paper
• Predicted biological activity of intravitreal VEGF Trap

  2008cited by this paper
• Pharmacokinetics of intravitreal bevacizumab (Avastin).

  2007cited by this paper
• Pharmacokinetics of intravitreal ranibizumab (Lucentis).

  2007cited by this paper
• PHARMACOKINETICS AND RETINAL DISTRIBUTION OF RANIBIZUMAB, A HUMANIZED ANTIBODY FRAGMENT DIRECTED AGAINST VEGF-A, FOLLOWING INTRAVITREAL ADMINISTRATION IN RABBITS

  2007cited by this paper
• Ranibizumab for neovascular age-related macular degeneration.

  2006cited by this paper
• The pharmacokinetics of rituximab following an intravitreal injection.

  2006cited by this paper
• Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

  2006cited by this paper
• Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.

  2005cited by this paper
• VEGF-Trap: A VEGF blocker with potent antitumor effects

  2002cited by this paper

• Surface Modification and Pore Size Regulation of MSN as Function Aflibercept Carrier for Anti-Vascular Migration

  2025cites this paper
• Topical delivery of anti-VEGF macromolecules for retinopathy: A review.

  2025cites this paper
• Effect of Combination Use of Aqueous Humor Secretion Inhibitor Eye Drops on Aflibercept Level: A Preliminary Analysis

  2025cites this paper
• Comparative Pharmacokinetic Analysis of Aflibercept and Brolucizumab in Human Aqueous Humor Using Nano-Surface and Molecular-Orientation Limited Proteolysis

  2025influential citation
• Comparative study on the efficacy of Conbercept and Aflibercept in the treatment of neovascular age-related macular degeneration

  2024influential citation
• Advances in nanomedicine for retinal drug delivery: overcoming barriers and enhancing therapeutic outcomes

  2024influential citation
• Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds

  2023cites this paper
• Biomaterial Drug Delivery Systems for Prominent Ocular Diseases

  2023cites this paper
• Advancing treatment of retinal disease through in silico trials

  2023cites this paper
• Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration

  2022cites this paper
• Secondary glaucoma following vitreo-retinal surgeries

  2022cites this paper
• Pharmacokinetic evaluation of radiolabeled intraocular anti‐CLEC14a antibody in preclinical animal species and application in humans

  2022cites this paper
• Systemic and Ocular Adverse Events with Intravitreal Anti-VEGF Therapy Used in the Treatment of Diabetic Retinopathy: a Review

  2022cites this paper
• Microvolume Analysis of Aflibercept in Aqueous Humor Using Mass Spectrometry

  2022cites this paper
• The emerging role of the Angiopoietin-Tie pathway as therapeutic target for treating retinal diseases

  2022cites this paper
• Ocular Drug Delivery to the Retina: Current Innovations and Future Perspectives

  2021cites this paper
• Permeability of the Retina and RPE-Choroid-Sclera to Three Ophthalmic Drugs and the Associated Factors

  2021cites this paper
• Novel hybrid lipid nanocapsules loaded with a therapeutic monoclonal antibody - Bevacizumab - and Triamcinolone acetonide for combined therapy in neovascular ocular pathologies.

  2021cites this paper
• Nanoparticulate Drug Delivery to the Retina.

  2020cites this paper
• Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives

  2020cites this paper
• Intraocular Pharmacokinetics of 10-fold Intravitreal Ranibizumab Injection Dose in Rabbits

  2020cites this paper
• Intravitreal Pharmacokinetic Study of the Antiangiogenic Glycoprotein Opticin

  2020cites this paper
• Preclinical challenges for developing long acting intravitreal medicines.

  2020cites this paper
• Intraocular Distribution and Kinetics of Intravitreally Injected Antibodies and Nanoparticles in Rabbit Eyes

  2020cites this paper
• Preclinical Efficacy and Safety of VEGF-Grab, a Novel Anti-VEGF Drug, and Its Comparison to Aflibercept

  2020cites this paper
• New Ocular Drug Delivery Systems

  2020cites this paper
• Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives

  2020cites this paper
• Treatment Course of Patients with Exudative Age-Related Macular Degeneration Using Ocular Hypotensives

  2020cites this paper
• Effect of Aflibercept on Human Corneal Endothelial Cells in Neovascular Age-Related Macular Degeneration: A Pilot Study Neovasküler Tip yaşa Bağlı Makula Dejenerasyonunda Uygulanan İntravitreal Aflibercept Tedavisinin Korneal Endotel Hücreleri Üzerine Etkisi: Pilot Bir Çalışma

  2019cites this paper
• A Translational Approach to Enzyme-Mediated Retinal Lipofuscin Removal for Atrophic Age-Related Macular Degeneration and Stargardt's Disease

  2019cites this paper
• EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.

  2019cites this paper
• Contact Lens Based Drug Delivery to the Posterior Segment Via Iontophoresis in Cadaver Rabbit Eyes

  2019cites this paper
• A Prediction Model for the Intraocular Pharmacokinetics of Intravitreally Injected Drugs Based on Molecular Physicochemical Properties

  2019cites this paper
• Construction of digital three-dimensional reconstruction model of rabbit vascular network

  2019cites this paper
• Controlled release technology for anti‐angiogenesis treatment of posterior eye diseases: Current status and challenges

  2018cites this paper
• Clinical pharmacology of intravitreal anti-VEGF drugs

  2018cites this paper
• Recombinant Manganese Peroxidase Reduces A2E Burden in Age-Related and Stargardt's Macular Degeneration Models

  2018cites this paper
• A Controlled Release System for Long-Acting Intravitreal Delivery of Small Molecules

  2018cites this paper
• SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB

  2017cites this paper
• Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes

  2017cites this paper
• Preclinical PET Study of Intravitreal Injections.

  2017cites this paper
• Pharmacokinetic aspects of retinal drug delivery.

  2017influential citation
• Recent perspectives on the delivery of biologics to back of the eye

  2017cites this paper
• Vitreoretinal interface abnormalities in diabetic macular edema and effectiveness of anti-VEGF therapy: an optical coherence tomography study

  2017cites this paper
• Role of the Fc Region in the Vitreous Half-Life of Anti-VEGF Drugs.

  2017cites this paper
• Ogólnoustrojowa farmakokinetyka leków anty-VEGF podawanych doszklistkowo w leczeniu wysiękowego AMD

  2016cites this paper
• Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs.

  2016cites this paper
• Diabetic macular oedema: pathophysiology, management challenges and treatment resistance

  2016cites this paper
• Intraocular Pharmacokinetics of Intravitreal Aflibercept (Eylea) in a Rabbit Model.

  2016cites this paper